HIV Resistance Primer

Question 1

M184V (or I) confers COMPLETE resistance to:

Answer 1

lamivudine (3TC) and
emtricitabine (FTC).

These drugs have a low barrier to resistance.

Question 2

M184V (or I) enhances the virologic activity to:

Answer 2

zidovudine (ZDV) and tenofovir (TDF)

Question 3

K65R is selected by ______ and confers resistance to ALL ____ except ______ .
. .

Answer 3

tenofovir (TDF/TAF)

ALL NRTI

except zidovudine (ZDV)

Question 4

K103N is the signature mutation for:

Answer 4

efavirenz (EFV).

Question 5

Y181C is the signature mutation for:

Answer 5

nevirapine (NVP).

Question 6

efavirenz and nevirapine, have a low genetic barrier

Answer 6

and are COMPLETELY cross-resistant to one another.

Question 7

E138K is the signature mutation for:

Answer 7

rilpivirine (RPV) and etravirine (ETR).

Question 8

E138K, K101E, and/or Y181C

Answer 8

Rilpivirine or etravirine and consequently,

resistance to ALL NNRTIs.

Question 9

I50L confers resistance to:

Answer 9

atazanavir (ATV)

Question 10

Q148 mutation decreases activity of:

Answer 10

Dolutegravir (DTG) and bictegravir (BIC)

Question 11

The MoCo mech of virologic failure for Maraviroc is:

Answer 11

Selection of pre-existing X4 virus (X4

or D/M on tropism test).